

# **Multivalent Interactions**


**Literature Seminar  
M2 Miura Kensuke**

# Outline

- **Introduction of multivalency inspired by living system**
- Multivalency by artificial material
- Main topic:  
“Heteromultivalent peptide recognition by co-assembly of cyclodextrin and calixarene amphiphiles enables inhibition of amyloid fibrillation”  
(Xu, Z.; Jia, S.; Wang, W; Yuan, Z.; Ravoo, J. B.; Guo, S. D. *Nat. Chem.* 2019, 11, 86-93.)

# The Concept of Multivalent Interactions

## Monovalent Interaction




## Multivalent Interactions


simultaneous interactions of multiple copies of the same ligand and receptor

↓


Improvement of binding affinity




# Adhesion of a Influenza Virus to the Surface of a Cell Example of Multivalency in Living systems




# Antibodies and Macrophage Example of Multivalency in Living Systems




# Free Energy and Binding Constants in Multivalent Interactions




# Evaluation of multivalency



# The Concept of Heteromultivalent Interactions




**Heteromultivalency**  
= "multivalent" + "heterotopic"



**Heteromultivalency results in greater strength and specificity than homomultivalency**

# The Example of Heteromultivalency in living system




# Outline


- Introduction of multivalency inspired by living system
- Multivalency by artificial material
- Main topic:  
“Heteromultivalent peptide recognition by co-assembly of cyclodextrin and calixarene amphiphiles enables inhibition of amyloid fibrillation”  
(Xu, Z.; Jia, S.; Wang, W; Yuan, Z.; Ravoo, J. B.; Guo, S. D. *Nat. Chem.* 2019, 11, 86-93.)

# Application of Multivalent interactions




scaffold




monomer



# Host-Guest Chemistry



Cucurbit[n]uril



Calix[n]arene

## Host-Guest Chemistry

■ selective binding: hydrogen bonding, ionic bonds, van der Waals forces, hydrophobic interactions (**non-covalent bonding**)  
Other factors: size, shape of molecule




## Application to molecular recognition

■ biological application: reinforcing tissue adhesion<sup>1)</sup>, targeted drug delivery<sup>2)</sup>


1) Thi, T. T. H. et al. *ACS Macro Lett.* **2017**, 6, 83 .

2) Namgung, R. et al. *ACS Macro Lett.* **2017**, 6, 83

# Recognition of Side Chain by Synthetic Host Molecule




b  
sclx4




CLR01

Trp-Gly-Gly





CB[8]

Phe-Gly-Gly : Phe-Gly-Gly



# **Application of Heteromultivalency<sup>1), 2)</sup>**






## **Gb3: Globotriaosylceramide**

- 1) Lee, Y. S.; Cherla, P. R.; Caliskan, I.; Tesh, L. V. *Infect. Immun.* **2005**, *73*, 5115–5126 .  
 2) Miyachi, A.; Dohi, H.; Neri, P.; Mori, H.; Uzawa, H.; Seto, Y.; Nishida, Y. *Biomacromolecule.* **2005**, *73*,  
     5115–5126 .  
13

# **Application of Heteromultivalency**


# Heteroconjugated polymers bind Stx1 stronger than homoconjugated ones.




**IIIa:** *poly*[ $\alpha,\alpha$ GT+Glc/ AAm] (R = OH)  
**IIIa:** *poly*[ $\alpha,\alpha$ GT+GlcNAc/ AAm] (R = NHAc)

**Ia: homomultivalent ligand**  
**IIa, IIIa: heteromultivalent ligand**

# Drawback of Covalent Heteroconjugate



Inhibition of proper accomodation



proper accomodation

Other ligands can thwart proper accommodation




- More flexible and optimised frameworks are required
- Synthesis of best scaffolds is Intensive and time-consuming



# Outline

- Introduction of multivalency inspired by living system
- Multivalency by artificial material
- Main topic:  
**“Heteromultivalent peptide recognition by co-assembly of cyclodextrin and calixarene amphiphiles enables inhibition of amyloid fibrillation”**  
**(Xu, Z.; Jia, S.; Wang, W; Yuan, Z.; Ravoo, J. B.; Guo, S. D. *Nat. Chem.* 2019, 11, 86-93.)**


# Heteromultivalency by Co-assembling monomer






- Spontaneous assembly
- Non-covalent conjugation
- Flexibility





# Preparation of CD-CA Co-assembly



c)



# Preparation of CD-CA Co-assembly



## Abbreviation


YK  
YKY  
YKYK  
YKYKYK  
YYKK  
KYK  
KKK  
YKYYKY  
KYKKYK  
YKK

## Sequence




AcSYS(G)<sub>4</sub>SKSNH<sub>2</sub>  
AcSYS(G)<sub>4</sub>SKS(G)<sub>4</sub>SYSNH<sub>2</sub>  
AcSYS(G)<sub>4</sub>SKS(G)<sub>4</sub>SYS(G)<sub>4</sub>SKSNH<sub>2</sub>  
Ac(SYS(G)<sub>4</sub>SKS(G)<sub>4</sub>)<sub>2</sub>SYS(G)<sub>4</sub>SKSNH<sub>2</sub>  
AcSYS(G)<sub>4</sub>SYS(G)<sub>4</sub>SKS(G)<sub>4</sub>SKSNH<sub>2</sub>  
AcSKS(G)<sub>4</sub>SYS(G)<sub>4</sub>SKSNH<sub>2</sub>  
AcSKS(G)<sub>4</sub>SKS(G)<sub>4</sub>SKSNH<sub>2</sub>  
AcSYS(G)<sub>4</sub>SKS(G)<sub>4</sub>SYS(G)<sub>4</sub>SKS(G)<sub>4</sub>SYSNH<sub>2</sub>  
AcSKS(G)<sub>4</sub>SYS(G)<sub>4</sub>SKS(G)<sub>4</sub>SKS(G)<sub>4</sub>SYS(G)<sub>4</sub>SKSNH<sub>2</sub>  
AcSYS(G)<sub>4</sub>SKS(G)<sub>4</sub>SKSNH<sub>2</sub>

Amyloid  $\beta$ : DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA


# Introduction of Alzheimer's Disease




# Fluorescent Indicator Displacement Assay




determination of  $K_a$  (CA-lysine)



# Synergistic Effect of CD and CA




Synergistic Effect of  
heterotopic binding sites



Host	YK	YKY
$K_{\text{ave}}^{\text{a}}$	<b>CA</b> <b>CD-CA</b>	$(2.7 \pm 2.0) \times 10^3{}^{\text{b}}$ $(1.4 \pm 0.1) \times 10^4$
$K_{\text{multi}}^{\text{c}}$	<b>CA</b> <b>CD-CA</b>	$(2.7 \pm 2.0) \times 10^3{}^{\text{b}}$ $(1.4 \pm 0.1) \times 10^4$
		$(1.1 \pm 1.0) \times 10^3{}^{\text{b}}$ $(5.2 \pm 0.1) \times 10^4$

# Cooperativity and Enhancement




Parameter	YKYK	YKYKYK
$\beta^a$	$(1.6 \pm 0.3) \times 10^6$	$(1.9 \pm 0.6) \times 10^{14}$
$\alpha^b$	$1.2 \pm 0.1$	$1.5 \pm 0.1$

- this case is positively cooperative ( $\alpha > 1$ )
- drastic increase of  $\beta$
- evidence of multivalent interaction

	Host	YK	YKYK	YKYKYK
$K_{ave}^a$	<b>CA</b>	$(2.7 \pm 2.0) \times 10^3 b$	$(6.1 \pm 0.3) \times 10^4$	$(3.0 \pm 0.3) \times 10^5$
	<b>CD-CA</b>	$(1.4 \pm 0.1) \times 10^4$	$(1.5 \pm 0.1) \times 10^5$	$(1.4 \pm 0.1) \times 10^6$
$K_{multi}^c$	<b>CA</b>	$(2.7 \pm 2.0) \times 10^3 b$	$(3.7 \pm 0.4) \times 10^9$	$(2.7 \pm 0.8) \times 10^{16}$
	<b>CD-CA</b>	$(1.4 \pm 0.1) \times 10^4$	$(2.3 \pm 0.3) \times 10^{10}$	$(2.7 \pm 0.6) \times 10^{18}$

# Homomultivalency vs Heteromultivalency




Host	YKYKYK	KKK
$K_{\text{ave}}^{\text{a}}$	<b>CA</b> $(3.0 \pm 0.3) \times 10^5$	$(4.6 \pm 0.5) \times 10^5$
	<b>CD-CA</b> $(1.4 \pm 0.1) \times 10^6$	$(2.2 \pm 0.3) \times 10^5$
$K_{\text{multi}}^{\text{c}}$	<b>CA</b> $(2.7 \pm 0.8) \times 10^{16}$	$(9.7 \pm 3.2) \times 10^{16}$
	<b>CD-CA</b> $(2.7 \pm 0.6) \times 10^{18}$	$(1.1 \pm 0.4) \times 10^{16}$

# Self-adapting of CD-CA to Model Peptide


Host	YKYK	YYKK
$K_{\text{ave}}^{\text{a}}$	<b>CA</b> $(6.1 \pm 0.3) \times 10^4$	<b>YYKK</b> $(6.3 \pm 0.2) \times 10^4$
	<b>CD-CA</b> $(1.5 \pm 0.1) \times 10^5$	$(1.4 \pm 0.1) \times 10^5$
$K_{\text{multi}}^{\text{c}}$	<b>CA</b> $(3.7 \pm 0.4) \times 10^9$	$(4.0 \pm 0.3) \times 10^9$
	<b>CD-CA</b> $(2.3 \pm 0.3) \times 10^{10}$	$(2.0 \pm 0.3) \times 10^{10}$

similar binding strength  
between YKYK and YYKK

- surface mobility
- self-optimization of spacing and sequence



# Self-adapting to Model Peptide



**[CD]:[CA]**

**2:1**

**1:1**

**1:2**

**YKYYKY**

$(4.2 \pm 0.3) \times 10^5$

$(4.5 \pm 0.2) \times 10^5$

$(5.4 \pm 0.2) \times 10^5$

**KYKKYK**


$(5.9 \pm 0.5) \times 10^6$

$(7.8 \pm 0.4) \times 10^6$


$(9.0 \pm 0.8) \times 10^6$

# Inhibition of amyloid fibrillation

## inhibition of A $\beta$ <sub>42</sub> aggregation



## disaggregation of A $\beta$ <sub>42</sub> fibrils







SC4A: sulfonatocalix[4]arene

dissolving preformed A $\beta$ <sub>42</sub> aggregation by  
CD-CA co-assembly




CD-CA co-assembly has potential in the  
application of Alzheimer's disease therapy

# Cell Viability Assay



# Conclusion



- Heteromultivalent molecular recognition was achieved by co-assembling different two macrocyclic receptor.
- Self-assembled heteromultivalent strategy is amenable to other ensembles and targets.